OVERVIEW

CJC-1295 no DAC (Mod GRF 1-29) is a synthetic peptide modeled after the first 29 amino acids of endogenous growth hormone-releasing hormone (GHRH). It is engineered to bind to GHRH receptors in the anterior pituitary, stimulating the natural release of growth hormone (GH). Unlike CJC-1295 formulations that include a drug affinity complex (DAC), the no-DAC version has a shorter half-life, typically promoting brief, pulsatile increases in GH levels that more closely resemble normal physiological secretion patterns. In research settings, Mod GRF 1-29 is used to study endocrine signaling, metabolic regulation, recovery processes, and downstream effects such as insulin-like growth factor-1 (IGF-1) production. By stimulating endogenous hormone release rather than introducing synthetic GH directly, it allows investigators to examine feedback mechanisms within the hypothalamic-pituitary axis.

Despite interest in laboratory and performance-oriented communities, CJC-1295 no DAC (Mod GRF 1-29) is not approved for therapeutic use by the U.S. Food and Drug Administration. Most available evidence comes from small studies, animal models, or mechanistic research rather than large, well-controlled human clinical trials. Products sold online are commonly labeled “for research use only,” meaning they are not regulated to pharmaceutical manufacturing standards, and quality or purity may vary. Because long-term safety, optimal dosing, and clinical effectiveness remain uncertain, self-administration outside approved research environments carries potential health and legal risks. Individuals concerned about hormone balance or metabolic health should seek guidance from qualified healthcare professionals and rely on established medical treatments.